Cart
sales@molnova.com
SNS-314
CAS No. 1146618-41-8
SNS-314( SNS-314 Mesylate | SNS314 | SNS 314 )
Catalog No. M10517 CAS No. 1146618-41-8
SNS-314 is a potent, selective pan-Aurora kinase inhibitor with IC50 of 9 and 31 nM for Aurora A and Aurora B, repectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 48 | In Stock |
|
| 5MG | 76 | In Stock |
|
| 10MG | 115 | In Stock |
|
| 25MG | 222 | In Stock |
|
| 50MG | 308 | In Stock |
|
| 100MG | 447 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSNS-314
-
NoteResearch use only, not for human use.
-
Brief DescriptionSNS-314 is a potent, selective pan-Aurora kinase inhibitor with IC50 of 9 and 31 nM for Aurora A and Aurora B, repectively.
-
DescriptionSNS-314 is a potent, selective pan-Aurora kinase inhibitor with IC50 of 9 and 31 nM for Aurora A and Aurora B, repectively; demonstrates broad activity in vitro against multiple human cancer cell lines and exhibits significant in vivo activity against a wide range of tumor xenograft models; shows additive antiproliferative effects with carboplatin, gemcitabine, 5-FU, daunomycin, and SN-38 both in vitro and in vivo.Solid Tumors Phase 1 Discontinued(In Vitro):SNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC50 values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells.(In Vivo):In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off.
-
In VitroSNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC50 values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells.
-
In VivoIn the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off.
-
SynonymsSNS-314 Mesylate | SNS314 | SNS 314
-
PathwayCell Cycle/DNA Damage
-
TargetAurora Kinase
-
RecptorAuroraA|AuroraB|AuroraC
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1146618-41-8
-
Formula Weight527.04
-
Molecular FormulaC19H19ClN6O4S3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCS(=O)(=O)O.C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4
-
Chemical NameUrea, N-(3-chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]-, methanesulfonate (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Oslob JD, et al. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4.
2. VanderPorten EC, et al. Mol Cancer Ther. 2009 Apr;8(4):930-9.
3. Arbitrario JP, et al. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
molnova catalog
related products
-
Danusertib
A potent, ATP-competitive Aurora kinase inhibitor with IC50 of 13,79 and 61 nM for Aurora A, B and C, respectively; Also inhibits Abl, RET, and FGFR1 (IC50=25,31, and 47 nM).
-
Aurora Kinase Inhibi...
Aurora Kinase Inhibitor II is a cell-permeable anilinoquinazoline that inhibit the activity of Aurora A (IC50 = 0.39 M).
-
AS 703569
Cenisertib (AS 703569;R763) is a novel potent, orally available inhibitor of Aurora kinases, exhibits signifficant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo (A549 EC50=9 nM).
